Impaired inhibition of NF-κB activity by melanoma-associated p16INK4a mutations

被引:15
作者
Becker, TM [1 ]
Rizos, H
de la Pena, A
Leclercq, IA
Woodruff, S
Kefford, RF
Mann, GJ
机构
[1] Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia
[2] Univ Sydney, Westmead Hosp, Dept Med, Storr Liver Unit, Westmead, NSW 2145, Australia
[3] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead, NSW 2145, Australia
[4] Univ Catholique Louvain, Lab Gastroenterol, B-1200 Brussels, Belgium
基金
英国医学研究理事会;
关键词
p16INK4a; tumor suppressor; cell cycle; NF-kappa B; transcription factor;
D O I
10.1016/j.bbrc.2005.05.032
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The cyclin-dependent kinase inhibitor p16INK4a has been identified as tumor suppressor and melanoma predisposition gene. While its cell cycle inhibitory ability is important in protecting cells from uncontrolled growth and possible tumor formation, other functions of p16INK4a are likely to contribute to its nature as a tumor suppressor. p16INK4a binding and inhibition of the transcription factor NF-kappa B has been shown and is consistent with the reports of abnormally increased NF-kappa B activity in various cancers including melanoma. Here, we present evidence that wild type p16INK4a binds to the NF-kappa B subunit RelA more efficiently than melanoma-associated p16INK4a mutations. Furthermore, whereas wild type p16INK4a strongly inhibits NF-kappa B transcriptional activity, a subset of melanoma-associated p16INK4a mutants show reduced NF-kappa B; inhibitory function. p16INK4a does not affect NF-kappa B nuclear translocation or DNA binding. suggesting a mechanism that reduces NF-kappa B transactivation activity. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:873 / 879
页数:7
相关论文
共 32 条
[1]  
Becker TM, 2001, CLIN CANCER RES, V7, P3282
[2]   High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families [J].
Borg, Å ;
Sandberg, T ;
Nilsson, K ;
Johannsson, O ;
Klinker, M ;
Måsbäck, A ;
Westerdahl, J ;
Olsson, H ;
Ingvar, C .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (15) :1260-1266
[3]   A BIOMARKER THAT IDENTIFIES SENESCENT HUMAN-CELLS IN CULTURE AND IN AGING SKIN IN-VIVO [J].
DIMRI, GP ;
LEE, XH ;
BASILE, G ;
ACOSTA, M ;
SCOTT, C ;
ROSKELLEY, C ;
MEDRANO, EE ;
LINSKENS, M ;
RUBELJ, I ;
PEREIRASMITH, O ;
PEACOCKE, M ;
CAMPISI, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (20) :9363-9367
[4]   DIMERIZATION OF NF-KB2 WITH RELA(P65) REGULATES DNA-BINDING, TRANSCRIPTIONAL ACTIVATION, AND INHIBITION BY AN IKB-ALPHA (MAD-3) [J].
DUCKETT, CS ;
PERKINS, ND ;
KOWALIK, TF ;
SCHMID, RM ;
HUANG, ES ;
BALDWIN, AS ;
NABEL, GJ .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (03) :1315-1322
[5]   The role of NF-κB in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells [J].
Franco, AV ;
Zhang, XD ;
Van Berkel, E ;
Sanders, JE ;
Zhang, XY ;
Thomas, WD ;
Nguyen, T ;
Hersey, P .
JOURNAL OF IMMUNOLOGY, 2001, 166 (09) :5337-5345
[6]  
Holland EA, 1995, ONCOGENE, V11, P2289
[7]  
Huang S, 2000, CLIN CANCER RES, V6, P2573
[8]   p16INK4a and the control of cellular proliferative life span -: Commentary [J].
Huschtscha, LI ;
Reddel, RR .
CARCINOGENESIS, 1999, 20 (06) :921-926
[9]   Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the melanoma genetics consortium [J].
Kefford, RF ;
Bishop, JAN ;
Bergman, W ;
Tucker, MA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3245-3251
[10]   An NF-κB-specific inhibitor, IκBα, binds to and inhibits cyclin-dependent kinase 4 [J].
Li, JN ;
Joo, SH ;
Tsai, MD .
BIOCHEMISTRY, 2003, 42 (46) :13476-13483